Investing.com — Bernstein analysts are optimistic about the European pharmaceutical sector as it heads into 2025, despite concerns over policy changes and market headwinds.
The firm outlined its three key reasons for the positive outlook in a note this week
Solid Growth Prospects: Bernstein forecasts an 8% EPS compound annual growth rate (CAGR) from 2025 to 2030, excluding Novo Nordisk…
Get the Nike Air Force 1 for $100 or Less
SHOP NOW
3 reasons Bernstein strategists are bullish on the EU pharma sector into 2025 By Investing.com
Business News
